William Hearl Email

President & CEO . Immunomic Therapeutics

Current Roles

Employees:
38
Revenue:
$2.9M
About
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
Immunomic Therapeutics Address
15010 Broschart Road
Rockville, MD
United States
Immunomic Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.